Covered recipient · General Payments record
MICHAEL A BURNSTINE
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2018–2024
$6,089.97
- Reported across 56 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Royalty or License | $726.66 | 1 |
| Food and Beverage | $421.75 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Poriferous LLC | $726.66 | 1 |
| Amgen Inc. | $386.09 | 17 |
| Tarsus Pharmaceuticals, Inc. | $35.66 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $8.47 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471340 | CMS |
| Amgen Inc. | $13.35 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471347 | CMS |
| Amgen Inc. | $16.65 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471353 | CMS |
| Amgen Inc. | $7.55 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471359 | CMS |
| Amgen Inc. | $6.78 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471364 | CMS |
| Amgen Inc. | $22.36 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471371 | CMS |
| Amgen Inc. | $6.33 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471378 | CMS |
| Amgen Inc. | $11.23 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471384 | CMS |
| Amgen Inc. | $12.06 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471390 | CMS |
| Amgen Inc. | $8.52 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471400 | CMS |
| Amgen Inc. | $16.22 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471405 | CMS |
| Amgen Inc. | $10.22 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471415 | CMS |
| Amgen Inc. | $150.00 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471422 | CMS |
| Amgen Inc. | $15.93 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471425 | CMS |
| Amgen Inc. | $34.86 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471431 | CMS |
| Amgen Inc. | $34.72 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471435 | CMS |
| Amgen Inc. | $10.84 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115471442 | CMS |
| Poriferous LLC | $726.66 | 12/31/2024 | Royalty or License | Undisputed | 01/23/2026 | 1082127261 | CMS |
| Tarsus Pharmaceuticals, Inc. | $35.66 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139086004 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.